Display options
Cite
Moon MK, Hur KY, Ko SH, et al. Combination Therapy of Oral Hypoglycemic Agents in Patients with Type 2 Diabetes Mellitus. Diabetes Metab J. 2017;41(5):357-366doi: 10.4093/dmj.2017.41.5.357.
Moon, M. K., Hur, K. Y., Ko, S. H., Park, S. O., Lee, B. W., Kim, J. H., Rhee, S. Y., Kim, H. J., Choi, K. M., Kim, N. H. (2017). Combination Therapy of Oral Hypoglycemic Agents in Patients with Type 2 Diabetes Mellitus. Diabetes & metabolism journal, 41(5), 357-366. https://doi.org/10.4093/dmj.2017.41.5.357
Moon, Min Kyong, et al. "Combination Therapy of Oral Hypoglycemic Agents in Patients with Type 2 Diabetes Mellitus." Diabetes & metabolism journal vol. 41,5 (2017): 357-366. doi: https://doi.org/10.4093/dmj.2017.41.5.357
Moon MK, Hur KY, Ko SH, Park SO, Lee BW, Kim JH, Rhee SY, Kim HJ, Choi KM, Kim NH. Combination Therapy of Oral Hypoglycemic Agents in Patients with Type 2 Diabetes Mellitus. Diabetes Metab J. 2017 Oct;41(5):357-366. doi: 10.4093/dmj.2017.41.5.357. PMID: 29086533; PMCID: PMC5663674.
Copy Download .nbib Format: NLM
Share it on

Diabetes Metab J. 2017 Oct;41(5):357-366. doi: 10.4093/dmj.2017.41.5.357.

Combination Therapy of Oral Hypoglycemic Agents in Patients with Type 2 Diabetes Mellitus.

Diabetes & metabolism journal

Min Kyong Moon, Kyu Yeon Hur, Seung Hyun Ko, Seok O Park, Byung Wan Lee, Jin Hwa Kim, Sang Youl Rhee, Hyun Jin Kim, Kyung Mook Choi, Nan Hee Kim,

Affiliations

  1. Department of Internal Medicine, Seoul Metropolitan Government Boramae Medical Center, Seoul National University College of Medicine, Seoul, Korea.
  2. Division of Endocrinology and Metabolism, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
  3. Division of Endocrinology and Metabolism, Department of Internal Medicine, College of Medicine, the Catholic University of Korea, Seoul, Korea.
  4. Department of Internal Medicine, Gwangmyeong Sungae Hospital, Gwangmyeong, Korea.
  5. Division of Endocrinology and Metabolism, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
  6. Division of Endocrinology and Metabolism, Department of Internal Medicine, Chosun University College of Medicine, Gwangju, Korea.
  7. Department of Endocrinology and Metabolism, Kyung Hee University School of Medicine, Seoul, Korea.
  8. Division of Endocrinology and Metabolism, Department of Internal Medicine, Chungnam National University School of Medicine, Daejeon, Korea.
  9. Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.
  10. Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea. [email protected].

PMID: 29086533 PMCID: PMC5663674 DOI: 10.4093/dmj.2017.41.5.357

Abstract

The Korean Diabetes Association (KDA) recently updated the Clinical Practice Guidelines on antihyperglycemic agent therapy for adult patients with type 2 diabetes mellitus (T2DM). In combination therapy of oral hypoglycemic agents (OHAs), general recommendations were not changed from those of the 2015 KDA guidelines. The Committee on Clinical Practice Guidelines of the KDA has extensively reviewed and discussed the results of meta-analyses and systematic reviews of effectiveness and safety of OHAs and many clinical trials on Korean patients with T2DM for the update of guidelines. All OHAs were effective when added to metformin or metformin and sulfonylurea, although the effects of each agent on body weight and hypoglycemia were different. Therefore, selection of a second agent as a metformin add-on therapy or third agent as a metformin and sulfonylurea add-on therapy should be based on the patient's clinical characteristics and the efficacy, side effects, mechanism of action, risk of hypoglycemia, effect on body weight, patient preference, and combined comorbidity. In this review, we address the results of meta-analyses and systematic reviews, comparing the effectiveness and safety among OHAs. It will help to choose the appropriate drug for an individual patient with T2DM.

Copyright © 2017 Korean Diabetes Association.

Keywords: Diabetes mellitus, type 2; Efficacy; Oral hypoglycemic agents; Practice guideline

Conflict of interest statement

No potential conflict of interest relevant to this article was reported.

References

  1. N Engl J Med. 2013 Oct 3;369(14):1317-26 - PubMed
  2. Int J Clin Pract. 2016 Feb;70(2):132-41 - PubMed
  3. Diabetologia. 2013 Dec;56(12):2582-92 - PubMed
  4. Diabetes Obes Metab. 2015 May;17(5):511-5 - PubMed
  5. Diabet Med. 2015 Dec;32(12 ):1530-40 - PubMed
  6. Clin Invest Med. 2016 Apr 02;39(2):E48-62 - PubMed
  7. Ann Intern Med. 2016 Jun 7;164(11):740-51 - PubMed
  8. Diabetes. 2011 May;60(5):1552-60 - PubMed
  9. Curr Med Res Opin. 2016 May;32(5):807-16 - PubMed
  10. Diabetes Care. 2011 Sep;34(9):2015-22 - PubMed
  11. Diabetes Care. 2014 Jun;37(6):1650-9 - PubMed
  12. Int J Clin Pract. 2015 Mar;69(3):292-304 - PubMed
  13. Diabetes Obes Metab. 2015 Mar;17(3):309-12 - PubMed
  14. PLoS One. 2015 May 20;10(5):e0124287 - PubMed
  15. Diabetes Res Clin Pract. 2016 Jun;116:149-58 - PubMed
  16. Diabetes Care. 2015 Mar;38(3):376-83 - PubMed
  17. PeerJ. 2015 Dec 07;3:e1461 - PubMed
  18. Ann Med. 2016;48(4):224-34 - PubMed
  19. Diabetes Obes Metab. 2016 Oct;18(10 ):1045-9 - PubMed
  20. Diabetes Care. 2014;37(1):9-16 - PubMed
  21. Lancet. 2013 Sep 14;382(9896):941-50 - PubMed
  22. N Engl J Med. 2013 Oct 3;369(14):1327-35 - PubMed
  23. N Engl J Med. 2016 Jul 28;375(4):323-34 - PubMed
  24. Diabetologia. 2013 Apr;56(4):696-708 - PubMed
  25. N Engl J Med. 2015 Jul 16;373(3):232-42 - PubMed
  26. Diabetes Obes Metab. 2017 May;19(5):635-643 - PubMed
  27. Diabetes Obes Metab. 2015 Jun;17(6):599-602 - PubMed
  28. Diabetes Care. 2012 Jun;35(6):1232-8 - PubMed
  29. JAMA. 2016 Jul 19;316(3):313-24 - PubMed
  30. N Engl J Med. 2015 Nov 26;373(22):2117-28 - PubMed
  31. Lancet Diabetes Endocrinol. 2014 Sep;2(9):691-700 - PubMed
  32. Korean J Intern Med. 2016 Sep;31(5):845-50 - PubMed
  33. Diabetes Res Clin Pract. 2015 Aug;109(2):378-88 - PubMed
  34. Diabetes Care. 2017 Jan;40(Suppl 1):S64-S74 - PubMed
  35. Diabetes Metab J. 2016 Jun;40(3):230-9 - PubMed
  36. Diabetes Res Clin Pract. 2015 Jul;109(1):141-8 - PubMed
  37. Diabetes Obes Metab. 2016 Aug;18(8):783-94 - PubMed
  38. Lancet. 2005 Oct 8;366(9493):1279-89 - PubMed
  39. Diabetes Metab J. 2017 Apr;41(2):135-145 - PubMed
  40. N Engl J Med. 2017 Aug 17;377(7):644-657 - PubMed
  41. Endocr Pract. 2017 Feb;23 (2):207-238 - PubMed
  42. Diabetes Care. 2015 Mar;38(3):384-93 - PubMed
  43. N Engl J Med. 2006 Dec 7;355(23):2427-43 - PubMed
  44. PLoS One. 2016 Nov 11;11(11):e0166125 - PubMed

Publication Types